Cogentus Pharmaceuticals, Inc.
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Cogentus Pharmaceuticals, Inc.
Hyloris Adds Aguettant Deals For Maxigesic IV In Europe
Hyloris has secured licensing deals with Aguettant for its Maxigesic IV combination of paracetamol and ibuprofen in a further eight European markets through partner AFT Pharmaceuticals.
2010 Scrip 100 - Survivors of the shakeout
Crunched credit wiped out many biotech firms in 2009, yet some emerged from the wreckage leaner and stronger. How did they do it, asks Dr Sukaina Virji-Jeganathan.
Constellation raises $17 million in private finance
Constellation Pharmaceuticals has secured $17.2 million in a third tranche of its $32 million series A financing round, and has appointed Dr Mark Goldsmith CEO and director.
New appointment at Constellation Pharmaceuticals
Constellation Pharmaceuticals, a US biopharmaceutical company discovering and developing drugs targeting epigenetic regulation of the human genome, has appointed Dr Mark Goldsmith chief executive officer and director. Dr Goldsmith was previously senior executive-in-residence at the healthcare venture capital firm Prospect Venture Partners. He has also served as co-founder and CEO of Cogentus Pharmaceuticals and senior vice-president of Genencor International.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice